XORTX Therapeutics Inc. competitors & alternatives

Enyo PharmaBiotechFrance

71% match

Biotech

ENYO Pharma is a clinical-stage biopharmaceutical company that develops therapeutics for patients with impaired kidney function. Its lead compound, Vonafexor, is a small molecule currently in Phase 2 development to treat rare kidney diseases such as Alport syndrome and chronic kidney disease.

R1 TherapeuticsLife SciencesUnited States

70% match

Life Sciences

R1 Therapeutics is a renal-focused biotech company developing innovative, first-in-class, category-defining therapeutics for patients with kidney disease. Headquartered in San Francisco with additional offices in San Diego and Raleigh, the company started with lead asset AP306.

Unicycive Therapeutics, Inc.UNCY · BiotechLos Altos, United States

70% matchPublic

Biotech

Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.

SironaxBiotechnologyChina

67% match

Similar biotechnology company

Sironax is a biopharmaceutical company committed to developing new treatments by targeting underlying contributors of degeneration, including neurodegenerative, inflammatory, and metabolic disorders.

Life Science

Synthorx, Inc., founded in 2014, is a biotechnology company headquartered in La Jolla, California, that engineered expanded genetic alphabet technologies to discover and develop novel protein therapeutics.

Centaurus Therapeutics, Inc.BiotechnologyUnited States

67% matchPrivate

Similar biotechnology company

Centaurus Therapeutics is a clinical-stage biotechnology company that develops first-in-class small-molecule therapies targeting ceramides to treat cardio-kidney-metabolic (CKM) diseases. The company's lead oral asset, CNT2130, inhibits DES1 to reduce excess ceramide production and restore lipid balance for patients suffering from organ decline.

UltragenyxBiotechJapan

67% matchAI 8/100 ▲Green 5/100 ▲

Biotech

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

Angitia BiopharmaceuticalsBiotechUnited States

67% match

Biotech

Angitia Biopharmaceuticals is a clinical-stage biotechnology company focused on discovering and developing innovative therapeutics for serious musculoskeletal diseases.

Biotech

ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.

ZyVersa Therapeutics, Inc.ZVSA · BiotechWeston, United States

67% matchPublic

Biotech

ZyVersa Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, dedicated to advancing and commercializing therapies for renal (kidney) and inflammatory disorders. The company's pipeline prominently features VAR 200, a cholesterol efflux modulator aimed at addressing kidney diseases such as focal segmental glomerulosclerosis, Alport syndrome, and diabetic kidney disease. Furthermore, ZyVersa is advancing IC 100, a pioneering inflammasome ASC inhibitor positioned to tackle a wide array of inflammatory conditions. The company maintains its corporate headquarters in Weston, Florida.

Sharp Therapeutics Corp.SHRX · BiotechCanada

66% matchPublic

Biotech

Sharp Therapeutics Corp. is a preclinical-stage biotechnology and drug discovery company that develops small molecule therapies to treat genetic diseases and hereditary disorders. The company combines high-speed experimentation and computational methods to advance its drug discovery platform.

Similar biotechnology company

XyloCor Therapeutics is a clinical-stage biopharmaceutical company headquartered in King of Prussia, Pennsylvania, focused on developing novel gene therapies for advanced coronary artery disease. The company is dedicated to improving patient outcomes through innovative cardiovascular treatments.